• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events

    6/24/25 8:00:14 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPTH alert in real time by email
    0001133818false00011338182025-06-202025-06-20

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT PURSUANT

    TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    ​

    Date of report (Date of earliest event reported): June 20, 2025

    ​

    BIO-PATH HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    ​

    Delaware

        

    001-36333

        

    87-0652870

    (State or other jurisdiction of incorporation)

    ​

    (Commission File Number)

    ​

    (IRS Employer Identification No.)

    ​

    ​

    ​

    4710 Bellaire Boulevard, Suite 210, Bellaire, Texas

        

    77401

    (Address of principal executive offices)

    ​

    (Zip Code)

    ​

    (832) 742-1357

    (Registrant’s Telephone Number, Including Area Code)

    ​

    (Former Name or Former Address, if Changed Since Last Report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading Symbol

        

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    BPTH

     

    N/A

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

    ​

    ​

    ​

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    ​

    Resignation of President and Chief Executive Officer

    ​

    On June 20, 2025, Peter H. Nielsen notified the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) of his decision to resign as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Principal Accounting Officer, Chairman of the Board, member of the Board and all committees of the Board on which he served for the Company.

    ​

    Resignation of Board Members

    ​

    On June 20, 2025, Heath Cleaver notified the Company of his decision to resign as a member of the Board and all committees of the Board on which he served. Mr. Cleaver’s resignation was not due to any disagreements with the Company or the Board.

    ​

    On June 21, 2025, Aline Sherwood notified the Company of her decision to resign as a member of the Board and all committees of the Board on which she served. Ms. Sherwood’s resignation was not due to any disagreements with the Company or the Board.

    ​

    Appointment of Chairman of the Board

    ​

    On June 22, 2025, the Board appointed Douglas P. Morris to serve as Chairman of the Board. There were no changes to Mr. Morris’s compensatory arrangements with the Company made in connection with his appointment as Chairman of the Board.

    ​

    Item 8.01 Other Events.

    ​

    The Company has instituted a Company-wide operational pause in order to conserve capital. The Company has furloughed most of its employees and paused most of its operations until further notice while the Company continues to seek financing or additional capital. The Board is currently discussing and evaluating a course of action in light of the Company’s limited capital resources, such operational pause and the resignations described above.

    ​

    As previously disclosed in the Company’s public filings, in the event that the Company is unable to secure financing or raise additional capital, it may be forced to (i) further delay, reduce the scope of or eliminate one or more of the Company’s drug development programs, (ii) relinquish, license or otherwise dispose of rights to technologies, drug candidates or products that it would otherwise seek to develop or commercialize at an earlier stage or on terms that are less favorable than might otherwise be available or (iii) liquidate and dissolve the Company. There can be no assurance that the Company will be able to raise additional capital when needed or on terms that are favorable to it, if at all. 

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

     

    BIO-PATH HOLDINGS, INC.  

     

     

     

    ​

    ​

    ​

    Dated: June 24, 2025

    By:

    /s/ Douglas P. Morris

     

     

    Douglas P. Morris

     

     

    Chairman of the Board

    ​

    ​

    Get the next $BPTH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BPTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Bio-Path

      Roth Capital initiated coverage of Bio-Path with a rating of Buy

      3/11/21 7:29:52 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH Capital initiated coverage on Bio-Path with a new price target

      ROTH Capital initiated coverage of Bio-Path with a rating of Buy and set a new price target of $13.00

      3/11/21 7:25:18 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Life Sciences Investor Forum: Now Available for Online Viewing

      NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

      6/13/25 8:35:00 AM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Life Sciences Investor Forum Agenda Announced for June 11th-12th

      NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

      6/10/25 2:38:09 PM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

      HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced Peter Nielsen, Chief Executive Officer, will present a corporate overview at the Life Sciences Virtual Investor Forum on Thursday, June 12 at 12:00 p.m. ET. A live stream of the presentation will be available here and on the Investor Relations section of Bio-Path's website, where it will be archived for approximately 90 days. About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize®, a

      6/9/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    SEC Filings

    See more
    • Bio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events

      8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      6/24/25 8:00:14 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 253G3 filed by Bio-Path Holdings Inc.

      253G3 - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      6/2/25 4:35:21 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form QUALIF filed by Bio-Path Holdings Inc.

      QUALIF - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      5/30/25 12:15:10 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Sherwood Aline

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:14:31 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aubert Paul

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:10:56 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cleaver Heath

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:07:55 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

      HOUSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Aline Sherwood to its Board of Directors on March 31, 2022. Ms. Sherwood replaced Martina Molsbergen, who stepped down from the Board of Directors on February 14, 2022. "We are delighted to welcome Aline to the Bio-Path Board of Directors. With her extensive background in biotechnology communications, Aline synthesizes complex science into compelling messaging, which is instrumental in guiding our communications

      4/6/22 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Financials

    Live finance-specific insights

    See more
    • Bio-Path Holdings Provides Clinical and Operational Update

      HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

      6/3/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

      HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

      5/22/25 4:30:00 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings Reports Full Year 2024 Financial Results

      HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. "We are merely touching the tip of the iceberg in terms of realizing the potential of our DNAbilize® platform to change the treatment paradigm in both obesity and oncology," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Throughout the last year, we built on the bo

      3/28/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

      SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

      11/13/24 11:15:11 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

      SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

      11/6/24 4:52:04 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bio-Path Holdings Inc.

      SC 13G - BIO-PATH HOLDINGS INC (0001133818) (Subject)

      4/3/24 5:44:32 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care